Improved assay for fecal calprotectin

被引:171
作者
Ton, H [1 ]
Brandsnes, O
Dale, S
Holtlund, J
Skuibina, E
Schjonsby, H
Johne, B
机构
[1] Nycomed Pharma AS, Oslo, Norway
[2] Parexel Medstat Res, Lillestrom, Norway
[3] Aker Univ Hosp, Oslo, Norway
关键词
calprotectin; feces; ELISA;
D O I
10.1016/S0009-8981(99)00206-5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Fecal calprotectin is a marker of inflammatory and neoplastic disease in the lower gastrointestinal tract. A new fecal sample preparation procedure for the measurement of calprotectin has been developed, with higher calprotectin yield and lower contamination risk. Changes in the new method compared to the original [Roseth AG, Fagerhol MK, Aadland E, Schonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27(9):793-798] are smaller sample size, higher dilution of the sample, presence of dissociating agents in the extraction solution and procedure performed in closed disposable tubes. The extraction yield was 78% (41-100%) of total calprotectin, giving an overall five-fold increase compared to the original method. Samples with high calprotectin values were increased to a slightly higher degree, than low calprotectin samples, thus improving the separation between high and low calprotectin levels. Median calprotectin level in healthy subjects was 26 mu g/g. Pathological samples with pancolitis showed levels up to 30 000 mu g/g. The mean C.V. (coefficient of variation) in blended feces was lower than that of unblended, suggesting uneven distribution of calprotectin. However, no significant difference between spot measurements was found when five samples from each of 47 stools were measured. Thus measurements of calprotectin in fecal samples were accurate and reproducible. No interference with foods or relevant oral pharmaceuticals or nutraceuticals was found. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:41 / 54
页数:14
相关论文
共 37 条
[1]  
ALTMAN DG, 1996, PRACTICAL STAT MED R
[2]  
Berntzen H B, 1988, Scand J Rheumatol Suppl, V76, P251
[3]  
BERNTZEN HB, 1991, J RHEUMATOL, V18, P133
[4]   L1, A MAJOR GRANULOCYTE PROTEIN - ISOLATION OF HIGH QUANTITIES OF ITS SUBUNITS [J].
BERNTZEN, HB ;
FAGERHOL, MK .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1990, 50 (07) :769-774
[5]   DISTRIBUTION OF A FORMALIN-RESISTANT MYELOMONOCYTIC ANTIGEN (L1) IN HUMAN-TISSUES .2. NORMAL AND ABERRANT OCCURRENCE IN VARIOUS EPITHELIA [J].
BRANDTZAEG, P ;
DALE, I ;
FAGERHOL, MK .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (06) :700-707
[6]  
CLOHESSY PA, 1996, BIOCHEM SOC T, pS309
[7]  
Courtheyn Dirk, 1994, Food and Agricultural Immunology, V6, P131, DOI 10.1080/09540109409354822
[8]   DISTRIBUTION OF A NEW MYELOMONOCYTIC ANTIGEN (L1) IN HUMAN PERIPHERAL-BLOOD LEUKOCYTES - IMMUNOFLUORESCENCE AND IMMUNOPEROXIDASE STAINING FEATURES IN COMPARISON WITH LYSOZYME AND LACTOFERRIN [J].
DALE, I ;
BRANDTZAEG, P ;
FAGERHOL, MK ;
SCOTT, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1985, 84 (01) :24-34
[9]   PURIFICATION AND PARTIAL CHARACTERIZATION OF A HIGHLY IMMUNOGENIC HUMAN-LEUKOCYTE PROTEIN, THE L1-ANTIGEN [J].
DALE, I ;
FAGERHOL, MK ;
NAESGAARD, I .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1983, 134 (01) :1-6
[10]   EXPRESSION OF THE EPITHELIAL L1 ANTIGEN AS AN IMMUNOHISTOCHEMICAL MARKER OF SQUAMOUS-CELL CARCINOMA OF THE LUNG [J].
DALE, I ;
BRANDTZAEG, P .
HISTOPATHOLOGY, 1989, 14 (05) :493-502